TECLens
TECLens is a clinical-stage medical device company developing qCXL, a non-invasive corneal cross-linking platform that uses personalized planning, patterned UV light, and real-time ultrasound to reshape the cornea for presbyopia and other refractive errors.
- Company typePrivate
- Founded2013
- HeadquartersStamford, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What TECLens does
TECLens is a clinical-stage medical device company developing a non-invasive approach to strengthening and reshaping the cornea for presbyopia and other refractive errors. It is also evaluating applications in hyperopia, adult and pediatric myopia, astigmatism, and keratoconus, with current activity centered on clinical development rather than commercial scale-up. Primary evidence:.
The qCXL platform uses personalized computational biomechanics treatment planning, patterned ultraviolet light delivered through a fiber optic-connected, single-use scleral contact lens called CXLens, and real-time ultrasound monitoring for closed-loop control. The system also includes a control console, UV and ultrasound hardware, proprietary trans-epithelial riboflavin, and treatment-planning software. TECLens states that the procedure does not cut or remove corneal tissue. Primary evidence:.
The planned business model combines capital-equipment sales for the control console with recurring per-procedure sales of disposable CXLens devices and riboflavin. TECLens plans direct B2B sales to ophthalmologists, optometrists, and eye-care practices, supported by training and clinical support, with procedures intended for an exam-room setting. Pricing, installed base, utilization, and current revenue are not disclosed. Primary evidence:.
TECLens firmographics
Firmographics- Name
- TECLens
- Legal name
- TECLens, Inc.
- Website
- https://teclens.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TECLens is a clinical-stage medical device company developing qCXL, a non-invasive corneal cross-linking platform that uses personalized planning, patterned UV light, and real-time ultrasound to reshape the cornea for presbyopia and other refractive errors.
- Ownership category
- akta.pro rank
TECLens industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Ophthalmic Goods (3851), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)
- akta.pro secondary industries
- Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG), Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF), Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
Keywords
Where TECLens is headquartered
LocationHeadquarters
- HQ city
- Stamford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
TECLens business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales: TECLens generates revenue through the sale of its CXLens® system - a capital equipment console and single-use disposable devices. The system includes a control system console, disposable treatment delivery devices, and the riboflavin drug formulation. The company plans to serve eye care professionals with a low-cost entry system.
- Consumables: Recurring revenue from single-use disposable contact lens devices (CXLens®) and proprietary riboflavin drug formulation used in each procedure.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
TECLens product offering
Product offeringCore offering
TECLens develops the qCXL™ system — a proprietary non-invasive corneal cross-linking platform centered on the single-use disposable CXLens® scleral contact lens, a control console, a proprietary trans-epithelial riboflavin formulation, and a computational treatment planning suite. The platform uses patterned ultraviolet light combined with real-time ultrasound monitoring to strengthen and reshape the cornea, addressing refractive errors (presbyopia, myopia, hyperopia, astigmatism) and keratoconus without cutting or removing tissue.
Product overview
TECLens offers a unified platform-based product ecosystem centered on its qCXL (Quantitative Corneal Cross-Linking) technology. The core system consists of four integrated components: the CXLens single-use disposable device (a fiber optic-connected scleral contact lens that delivers UV light), the Control Console (user interface with computer, UV and ultrasound systems), a proprietary trans-epithelial riboflavin photoactive drug, and a Computational Treatment Planning Suite (software that creates personalized treatment plans and monitors execution). These components work together as an integrated system for non-invasive corneal reshaping, with initial focus on presbyopia correction and applications for myopia, hyperopia, astigmatism, and keratoconus.
Differentiator
Problem solved
Functional benefit
Brands
- qCXL™: Quantitative Corneal Cross-Linking technology - proprietary technology designed to gently strengthen and reshape the cornea using ultraviolet light, addressing refractive errors including presbyopia.
- CXLens®
Quantifiable outcome
- Nearly 2 billion people worldwide affected by presbyopia
- +3 more outcomes
Companies that use TECLens
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
TECLens technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
TECLens partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- SERVImed Industrial SpacoreStrategic partnership to pursue U.S. FDA approval for trans-epithelial corneal cross-linking. Combines TECLens' CXLens® on-eye cross-linking system with SERVImed's RIBOCROSS riboflavin drug formulation. SERVImed holds FDA orphan drug designation for RIBOCROSS. Partnership aims to provide comfortable, non-invasive treatment for keratoconus and ectatic disorders.
- Asian Eye InstitutecoreClinical trial partner with Dr. Robert Ang, Refractive Surgery, Cataract, and Glaucoma Specialist, serving as Principal Clinical Study Investigator. Dr. Ang presented at Innovators Pop-Up during AAO 2025.
Scale indicators6 records
Recent moves5 records
Expansion highlights8 records
TECLens competitors and assessment
Company assessmentDirect peers
- Glaukos Corporation (Avedro): Glaukos acquired Avedro, the historical leader in corneal collagen cross-linking (CXL) systems and riboflavin formulations. Both companies are working in the same therapeutic modality (CXL for keratoconus and refractive indications) and target the same ophthalmologist customer base, making them the most direct peer to TECLens.
- Peschke Medizintechnik: European manufacturer of CXL systems (C-Eye and predecessors) and riboflavin solutions for corneal cross-linking. Peschke competes head-to-head in the same therapeutic category as TECLens, with similar UVA illumination platforms and riboflavin formulations, primarily in EU markets.
- Sooft Italia: Italian ophthalmic company selling riboflavin (Ricrolin) and other CXL adjuncts across Europe. Comparable to TECLens in supplying the photoactive drug component for trans-epithelial corneal cross-linking procedures.
- Ziemer Ophthalmic Systems: Swiss manufacturer of femtosecond lasers (LDV Z8) used in refractive and cataract surgery, with overlapping ophthalmic device DNA. Comparable in product engineering approach and physician-focused go-to-market.
Broad incumbents
- Carl Zeiss Meditec: Global leader in refractive surgical lasers (VISUMAX femtosecond for SMILE/LASIK) and ophthalmic diagnostics. Competes for refractive correction procedure volumes against TECLens across LASIK/SMILE despite operating an entirely different (tissue-removing) modality.
- Alcon: World's largest ophthalmic surgical company with WaveLight excimer and Contoura platforms for refractive surgery. As the dominant incumbent in vision correction, Alcon defines the standard of care TECLens aims to disrupt non-invasively.
- Johnson & Johnson Vision: Refractive and cataract surgery franchise (iDesign, STAR S4 IR excimer, TECNIS IOLs) and TECLens's own strategic investor via JJDC. As both incumbent and shareholder, J&J Vision frames both the competitive set and a potential exit pathway for TECLens.
- Bausch + Lomb: Major diversified ophthalmic company spanning contact lenses, IOLs (enVista, Toric), and LASIK excimer technology through Technolas. CTO Madhu Ayyagari's former employer; competes in refractive correction across multiple modalities.
Regional players
- Schwind eye-tech-solutions: German manufacturer of excimer (AMARIS) and femtosecond lasers for refractive surgery. Strong in European refractive surgery markets where TECLens already has trial sites, making it a relevant competitive reference in shared geographies.
Emerging players
- LENSAR: US-based company commercializing the ALLY robotic cataract and refractive system, also pursuing presbyopia-correcting IOLs. Smaller, growth-stage competitor targeting overlapping refractive and presbyopia correction indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TECLens social profiles
Digital presenceTECLens financial estimates
Financial estimateRevenue estimate
Valuation estimate
TECLens leadership team
Management profileNumber of profiles
TECLens funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TECLens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TECLens
What does TECLens do?
TECLens develops the qCXL™ system — a proprietary non-invasive corneal cross-linking platform centered on the single-use disposable CXLens® scleral contact lens, a control console, a proprietary trans-epithelial riboflavin formulation, and a computational treatment planning suite. The platform uses patterned ultraviolet light combined with real-time ultrasound monitoring to strengthen and reshape the cornea, addressing refractive errors (presbyopia, myopia, hyperopia, astigmatism) and keratoconus without cutting or removing tissue.
Is TECLens a public or private company?
TECLens is a private company. It is classified as venture growth investor backed and is currently operating.
When was TECLens founded?
TECLens was founded in 2013. It employs 11 to 50 people.
Where is TECLens based?
TECLens is headquartered in Stamford, United States, in the North America region.
How does TECLens make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are consumables.
Who are TECLens's main competitors?
Direct peers on record are Glaukos Corporation (Avedro), Peschke Medizintechnik, Sooft Italia and Ziemer Ophthalmic Systems. Broad incumbents are Carl Zeiss Meditec, Alcon, Johnson & Johnson Vision and Bausch + Lomb. Schwind eye-tech-solutions is listed as a regional player. LENSAR is listed as an emerging player.
Does TECLens have an API?
No public API is recorded for TECLens.
What industry is TECLens in?
TECLens's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAHAJAG, Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance). Its NAICS code is 339115 and its SIC code is 3851.